Lacosamide may improve cognition in patients with focal epilepsy: EpiTrack to compare cognitive side effects of lacosamide and carbamazepine

Carbamazepine (CBZ) is a first generation anti-seizure drug, considered as first choice therapy in focal epilepsy but associated with cognitive side effects. Lacosamide (LCM) is a third-generation anti-seizure drug approved for treating focal epilepsy. This case series documented the comparable effi...

Descripción completa

Detalles Bibliográficos
Autores principales: Liguori, Claudio, Izzi, Francesca, Manfredi, Natalia, Mercuri, Nicola Biagio, Placidi, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6030027/
https://www.ncbi.nlm.nih.gov/pubmed/29977793
http://dx.doi.org/10.1016/j.ebcr.2018.02.004
_version_ 1783337062571704320
author Liguori, Claudio
Izzi, Francesca
Manfredi, Natalia
Mercuri, Nicola Biagio
Placidi, Fabio
author_facet Liguori, Claudio
Izzi, Francesca
Manfredi, Natalia
Mercuri, Nicola Biagio
Placidi, Fabio
author_sort Liguori, Claudio
collection PubMed
description Carbamazepine (CBZ) is a first generation anti-seizure drug, considered as first choice therapy in focal epilepsy but associated with cognitive side effects. Lacosamide (LCM) is a third-generation anti-seizure drug approved for treating focal epilepsy. This case series documented the comparable efficacy of LCM and CBZ as first add on treatments in patients affected by uncontrolled focal seizures. LCM showed an increase in EpiTrack scores, which measure cognitive abilities, at follow-up compared to CBZ. This preliminary data may represent the basis for future prospective studies aimed at comparing the long-term cognitive side effects of LCM and CBZ.
format Online
Article
Text
id pubmed-6030027
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-60300272018-07-05 Lacosamide may improve cognition in patients with focal epilepsy: EpiTrack to compare cognitive side effects of lacosamide and carbamazepine Liguori, Claudio Izzi, Francesca Manfredi, Natalia Mercuri, Nicola Biagio Placidi, Fabio Epilepsy Behav Case Rep Article Carbamazepine (CBZ) is a first generation anti-seizure drug, considered as first choice therapy in focal epilepsy but associated with cognitive side effects. Lacosamide (LCM) is a third-generation anti-seizure drug approved for treating focal epilepsy. This case series documented the comparable efficacy of LCM and CBZ as first add on treatments in patients affected by uncontrolled focal seizures. LCM showed an increase in EpiTrack scores, which measure cognitive abilities, at follow-up compared to CBZ. This preliminary data may represent the basis for future prospective studies aimed at comparing the long-term cognitive side effects of LCM and CBZ. Elsevier 2018-03-12 /pmc/articles/PMC6030027/ /pubmed/29977793 http://dx.doi.org/10.1016/j.ebcr.2018.02.004 Text en © 2018 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Liguori, Claudio
Izzi, Francesca
Manfredi, Natalia
Mercuri, Nicola Biagio
Placidi, Fabio
Lacosamide may improve cognition in patients with focal epilepsy: EpiTrack to compare cognitive side effects of lacosamide and carbamazepine
title Lacosamide may improve cognition in patients with focal epilepsy: EpiTrack to compare cognitive side effects of lacosamide and carbamazepine
title_full Lacosamide may improve cognition in patients with focal epilepsy: EpiTrack to compare cognitive side effects of lacosamide and carbamazepine
title_fullStr Lacosamide may improve cognition in patients with focal epilepsy: EpiTrack to compare cognitive side effects of lacosamide and carbamazepine
title_full_unstemmed Lacosamide may improve cognition in patients with focal epilepsy: EpiTrack to compare cognitive side effects of lacosamide and carbamazepine
title_short Lacosamide may improve cognition in patients with focal epilepsy: EpiTrack to compare cognitive side effects of lacosamide and carbamazepine
title_sort lacosamide may improve cognition in patients with focal epilepsy: epitrack to compare cognitive side effects of lacosamide and carbamazepine
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6030027/
https://www.ncbi.nlm.nih.gov/pubmed/29977793
http://dx.doi.org/10.1016/j.ebcr.2018.02.004
work_keys_str_mv AT liguoriclaudio lacosamidemayimprovecognitioninpatientswithfocalepilepsyepitracktocomparecognitivesideeffectsoflacosamideandcarbamazepine
AT izzifrancesca lacosamidemayimprovecognitioninpatientswithfocalepilepsyepitracktocomparecognitivesideeffectsoflacosamideandcarbamazepine
AT manfredinatalia lacosamidemayimprovecognitioninpatientswithfocalepilepsyepitracktocomparecognitivesideeffectsoflacosamideandcarbamazepine
AT mercurinicolabiagio lacosamidemayimprovecognitioninpatientswithfocalepilepsyepitracktocomparecognitivesideeffectsoflacosamideandcarbamazepine
AT placidifabio lacosamidemayimprovecognitioninpatientswithfocalepilepsyepitracktocomparecognitivesideeffectsoflacosamideandcarbamazepine

Ejemplares similares